GSK files regulatory submission in EU for closed triple combination therapy FF/UMEC/VI
GlaxoSmithKline and Innoviva announced the filing by GSK of a regulatory submission with the EMA for once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) for patients with chronic obstructive pulmonary disease. December 02, 2016